市場調査レポート

商品コード

1771627

ウイルスワクチンCDMO市場規模、シェア、動向分析レポート：タイプ別、サービス別、ワークフロー別、最終用途別、地域別、セグメント予測、2025年～2033年

Viral Vaccines CDMO Market Size, Share & Trends Analysis Report By Type (Attenuated Vaccine, Inactivated Vaccine, DNA Vaccines, Subunit Vaccines), By Service, By Workflow, By End Use, By Region, And Segment Forecasts, 2025 - 2033

出版日: 2025年06月16日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日

カスタマイズ可能

価格

Unprintable PDF & Excel (Single User License)

USD 5,950 883,396円

レポートPDF及びExcelを1名様のみがご利用頂けるライセンスです。テキスト等のコピー＆ペースト、印刷はできません。

Printable PDF & Excel (5-User License)

USD 6,950 1,031,866円

レポートPDF及びExcelを同一企業内の同一部署における5名様までの方にご利用頂けるライセンスです。テキスト等のコピー＆ペースト、印刷は可能です。

Printable PDF & Excel (Enterprise License)

USD 8,950 1,328,806円

レポートの購入企業、およびその子会社、関連会社の方にご使用頂けるライセンスです。PDF及びExcelのテキスト等のコピー＆ペースト、印刷は可能です。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=148.47円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

ウイルスワクチンCDMO市場のサマリー

世界のウイルスワクチンCDMO市場規模は2024年に22億3,000万米ドルと推計され、2033年には73億9,000万米ドルに達すると予測され、2025年から2033年までのCAGRは15.1%で成長すると予測されます。同市場の成長は主に、感染症の流行増加、予防および治療用としてのウイルスベクターベースのプラットフォーム採用の増加、迅速でスケーラブルな製造ソリューションの必要性などを背景とした、ウイルスワクチンの製造委託に対する需要の高まりによるものです。

さらに、インフルエンザ、ヒトパピローマウイルス（HPV）、肝炎などのウイルス性疾患や、デング熱、RSV、ウイルス性出血熱のような新たな脅威の流行が増加していることから、官民のワクチン開発企業は、製造スケジュールを早める必要に迫られています。不活化ワクチンや組換えウイルスワクチンには高度なバイオセーフティ、品質、工程管理が要求されるため、製薬会社は確立されたウイルスプラットフォーム、BSL-2/3封じ込めインフラ、エンドツーエンドのコンプライアンス能力を持つCDMOを利用するようになっています。さらに、COVID-19以降、政府や国際保健機関はパンデミック対策への資金提供や長期調達契約を大幅に増やし、スケーラブルなウイルスワクチン製造への需要が高まっています。CDMOは、ウイルスシードバンキング、細胞株開発、ベクター工学、cGMPグレードのウイルス生産における専門知識を提供することで、ワクチンイノベーターが開発期間を短縮し、低い運用リスクで規制上のマイルストーンを達成できるようにしています。

シングルユースバイオリアクター、モジュラークリーンルーム、プレフィルドシリンジや凍結乾燥バイアルを含む高速充填仕上げラインの導入が進んでいるため、小規模バイオテクノロジー企業と大手ワクチン企業の双方にとって、アウトソーシングは効率的な選択肢となっています。さらに、複数の開発企業が新興国市場への進出を目指す中、米国FDA、EMA、WHO PQなどの複数地域の規制に準拠し、分散製造のフットプリントを持つCDMOが商業供給契約に好まれています。さらに、遺伝子治療や腫瘍学におけるウイルスベクター技術の台頭は、従来のワクチンと治療プラットフォームの境界線を不明確にしており、ウイルスCDMOサービスに対するクロスアプリケーションの需要を高めています。生物製剤がより個別化され技術的に複雑になるにつれ、ロンザ、富士フィルムダイオシンス、サムスンバイオロジクス、ウーシーバイオロジクスなどの企業は、上流のウイルス生産と下流の無菌充填仕上げの両方の能力を拡大し、世界のウイルスワクチン開発の次の時代における戦略的製造パートナーとしての地位を確立しつつあります。

地域ダッシュボード
地域別、2021年～2033年
北米
- 北米のウイルスワクチンCDMO市場推計・予測、2021年～2033年
- 米国
- カナダ
- メキシコ
欧州
- 欧州ウイルスワクチンCDMO市場推計・予測、2021年～2033年
- ドイツ
- 英国
- フランス
- イタリア
- スペイン
- デンマーク
- スウェーデン
- ノルウェー
アジア太平洋
- アジア太平洋地域のウイルスワクチンCDMO市場推計・予測、2021年～2033年
- 日本
- 中国
- インド
- 韓国
- オーストラリア
- タイ
ラテンアメリカ
- ラテンアメリカのウイルスワクチンCDMO市場推計・予測、2021年～2033年
- ブラジル
- アルゼンチン
中東・アフリカ
- 中東・アフリカのウイルスワクチンCDMO市場推計・予測、2021年～2033年
- 南アフリカ
- サウジアラビア
- アラブ首長国連邦
- クウェート

第9章競合情勢

企業分類
- マーケットリーダー
- 新興企業
Company Market Assessment Analysis, 2024
企業プロファイル
- Lonza
- Catalent Pharma
- Thermo Fisher Scientific
- Samsung Biologics
- Fujifilm Diosynth Biotechnologies
- WuXi Biologics
- Recipharm AB.
- HALIX BV
- Batavia Biosciences BV
- Alcami Corporation

図表

List of Tables

Table 1 List of abbreviations
Table 2 North America viral vaccines CDMO market estimates and forecasts, by region, 2021 - 2033 (USD Million)
Table 3 North America viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
Table 4 North America viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
Table 5 North America viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
Table 6 North America viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
Table 7 North America viral vaccines CDMO market estimates and forecasts, by country, 2021 - 2033 (USD Million)
Table 8 U.S. viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
Table 9 U.S. viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
Table 10 U.S. viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
Table 11 U.S. viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
Table 12 Canada viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
Table 13 Canada viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
Table 14 Canada viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
Table 15 Canada viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
Table 16 Mexico viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
Table 17 Mexico viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
Table 18 Mexico viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
Table 19 Mexico viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
Table 20 Europe viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
Table 21 Europe viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
Table 22 Europe viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
Table 23 Europe viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
Table 24 Europe viral vaccines CDMO market estimates and forecasts, by country, 2021 - 2033 (USD Million)
Table 25 UK viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
Table 26 UK viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
Table 27 UK viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
Table 28 UK viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
Table 29 Germany viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
Table 30 Germany viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
Table 31 Germany viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
Table 32 Germany viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
Table 33 France viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
Table 34 France viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
Table 35 France viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
Table 36 France viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
Table 37 Italy viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
Table 38 Italy viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
Table 39 Italy viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
Table 40 Italy viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
Table 41 Spain viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
Table 42 Spain viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
Table 43 Spain viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
Table 44 Spain viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
Table 45 Denmark viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
Table 46 Denmark viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
Table 47 Denmark viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
Table 48 Denmark viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
Table 49 Sweden viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
Table 50 Sweden viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
Table 51 Sweden viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
Table 52 Sweden viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
Table 53 Norway viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
Table 54 Norway viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
Table 55 Norway viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
Table 56 Norway viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
Table 57 Asia Pacific viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
Table 58 Asia Pacific viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
Table 59 Asia Pacific viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
Table 60 Asia Pacific viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
Table 61 Asia Pacific viral vaccines CDMO market estimates and forecasts, by country, 2021 - 2033 (USD Million)
Table 62 Japan viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
Table 63 Japan viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
Table 64 Japan viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
Table 65 Japan viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
Table 66 China viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
Table 67 China viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
Table 68 China viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
Table 69 China viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
Table 70 India viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
Table 71 India viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
Table 72 India viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
Table 73 India viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
Table 74 Australia viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
Table 75 Australia viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
Table 76 Australia viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
Table 77 Australia viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
Table 78 South Korea viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
Table 79 South Korea viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
Table 80 South Korea viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
Table 81 South Korea viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
Table 82 Thailand viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
Table 83 Thailand viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
Table 84 Thailand viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
Table 85 Thailand viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
Table 86 Latin America viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
Table 87 Latin America viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
Table 88 Latin America viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
Table 89 Latin America viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
Table 90 Latin America viral vaccines CDMO market estimates and forecasts, by country, 2021 - 2033 (USD Million)
Table 91 Brazil viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
Table 92 Brazil viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
Table 93 Brazil viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
Table 94 Brazil viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
Table 95 Argentina viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
Table 96 Argentina viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
Table 97 Argentina viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
Table 98 Argentina viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
Table 99 Middle East and Africa viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
Table 100 Middle East and Africa viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
Table 101 Middle East and Africa viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
Table 102 Middle East and Africa viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
Table 103 Middle East and Africa viral vaccines CDMO market estimates and forecasts, by country, 2021 - 2033 (USD Million)
Table 104 South Africa viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
Table 105 South Africa viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
Table 106 South Africa viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
Table 107 South Africa viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
Table 108 Saudi Arabia viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
Table 109 Saudi Arabia viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
Table 110 Saudi Arabia viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
Table 111 Saudi Arabia viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
Table 112 UAE viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
Table 113 UAE viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
Table 114 UAE viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
Table 115 UAE viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
Table 116 Kuwait viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
Table 117 Kuwait viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
Table 118 Kuwait viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
Table 119 Kuwait viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)

List of Figures

Fig. 1 Viral vaccines CDMO market segmentation
Fig. 2 Data analysis models
Fig. 3 Market formulation and validation
Fig. 4 Data validating & publishing
Fig. 5 Market research process
Fig. 6 Information procurement
Fig. 7 Primary research
Fig. 8 Value-chain-based sizing & forecasting
Fig. 9 QFD modelling for market share assessment
Fig. 10 Market formulation & validation
Fig. 11 Commodity flow analysis
Fig. 12 Market outlook
Fig. 13 Segment snapshot 1
Fig. 14 Segment snapshot 2
Fig. 15 Competitive landscape snapshot
Fig. 16 Porter's five force analysis
Fig. 17 PESTEL analysis
Fig. 18 Viral vaccines CDMO Market: Type outlook key takeaways
Fig. 19 Viral vaccines CDMO Market: Type movement analysis
Fig. 20 Attenuated vaccine market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 21 DNA vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 22 Subunit vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 23 viral vaccines CDMO Market: Services outlook key takeaways
Fig. 24 viral vaccines CDMO Market: Services movement analysis
Fig. 25 Formulation & process development market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 26 Upstream development market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 27 Downstream development market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 28 Analytical testing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 29 Fill-finish services market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 30 Packaging & labeling market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 31 Others market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 32 viral vaccines CDMO Market: Workflow outlook key takeaways
Fig. 33 viral vaccines CDMO Market: Workflow movement analysis
Fig. 34 Clinical market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 35 Commercial market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 36 Biopharmaceutical companies market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 37 Academic and research institutes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 38 Others market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 39 Regional marketplace outlook, 2024 & 2030 (USD Million)
Fig. 40 Regional marketplace: Key takeaways
Fig. 41 North America viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 42 Key country dynamics
Fig. 43 U.S. viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 44 Key country dynamics
Fig. 45 Canada viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 46 Key country dynamics
Fig. 47 Mexico viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 48 Key country dynamics
Fig. 49 Europe viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 50 Key country dynamics
Fig. 51 UK regulatory affairs market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 52 Key country dynamics
Fig. 53 Germany viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 54 Key country dynamics
Fig. 55 France viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 56 Key country dynamics
Fig. 57 Italy viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 58 Key country dynamics
Fig. 59 Spain viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 60 Key country dynamics
Fig. 61 Denmark viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 62 Key country dynamics
Fig. 63 Norway viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 64 Key country dynamics
Fig. 65 Sweden viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 66 Asia Pacific viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 67 Key country dynamics
Fig. 68 Japan viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 69 Key country dynamics
Fig. 70 China viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 71 Key country dynamics
Fig. 72 India viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 73 Key country dynamics
Fig. 74 Australia viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 75 Key country dynamics
Fig. 76 South Korea viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 77 Key country dynamics
Fig. 78 Thailand viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 79 Latin America viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 80 Key country dynamics
Fig. 81 Brazil viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 82 Key country dynamics
Fig. 83 Argentina viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 84 Key country dynamics
Fig. 85 MEA viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 86 Key country dynamics
Fig. 87 South Africa viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 88 Key country dynamics
Fig. 89 Saudi Arabia viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 90 Key country dynamics
Fig. 91 UAE viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 92 Key country dynamics
Fig. 93 Kuwait regulatory affairs market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 94 Market participant categorization
Fig. 95 Precision medicine market share/assessment analysis, 2024
Fig. 96 Strategic framework

Product Code: GVR-4-68040-624-6

Viral Vaccines CDMO Market Summary

The global viral vaccines CDMO market size was estimated at USD 2.23 billion in 2024 and is projected to reach USD 7.39 billion by 2033, growing at a CAGR of 15.1% from 2025 to 2033. The growth of the market is mainly due rising demand for outsourced manufacturing of viral vaccines, driven by increased prevalence of infectious diseases, growing adoption of viral vector-based platforms for both prophylactic and therapeutic use, and the need for rapid, scalable production solutions.

Furthermore,the increasing prevalence of viral illnesses such as influenza, human papillomavirus (HPV), hepatitis, and emerging threats like dengue, RSV, and viral hemorrhagic fevers has pushed public and private vaccine developers to accelerate production timelines. Given the high biosafety, quality, and process control requirements associated with live-attenuated, inactivated, and recombinant viral vaccines, pharmaceutical companies are increasingly turning to CDMOs with established viral platforms, BSL-2/3 containment infrastructure, and end-to-end compliance capabilities. Moreover, post-COVID-19, governments and global health agencies have significantly increased funding and long-term procurement agreements for pandemic preparedness, which has increased demand for scalable viral vaccine production. CDMOs offer specialized knowledge in viral seed banking, cell line development, vector engineering, and cGMP-grade virus production, enabling vaccine innovators to shorten development timelines and meet regulatory milestones with lower operational risk.

The growing adoption of single-use bioreactors, modular cleanrooms, and high-speed fill-finish lines including prefilled syringes and lyophilized vials has made outsourcing an efficient alternative for both small biotech firms and large vaccine players. Additionally, as several developers seek to expand into global markets, CDMOs with multi-regional regulatory compliance such as U.S. FDA, EMA, WHO PQ and distributed manufacturing footprints are favored for commercial supply contracts. Further, the rise of viral vector technologies in gene therapy and oncology has also unclear the lines between traditional vaccines and therapeutic platforms, increasing cross-application demand for viral CDMO services. As biologics become more personalized and technically complex, companies like Lonza, Fujifilm Diosynth, Samsung Biologics, and WuXi Biologics are scaling both upstream viral production and downstream sterile fill-finish capacities, positioning themselves as strategic manufacturing partners in the next era of global viral vaccine development.

Global Viral Vaccines CDMO Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2033. For this study, Grand View Research has segmented the global viral vaccines CDMO market report based on type, workflow, service, end use, and region.

Type Outlook (Revenue, USD Million, 2021 - 2033)
Attenuated Vaccine
Inactivated Vaccine
DNA Vaccines
Subunit Vaccines
Workflow Outlook (Revenue, USD Million, 2021 - 2033)
Clinical
Commercial
Service Outlook (Revenue, USD Million, 2021 - 2033)
Formulation & Process Development
- Upstream Development
- Downstream Development
Analytical Testing
Fill-Finish Services
Packaging & Labeling
Others
End Use Outlook (Revenue, USD Million, 2021 - 2033)
Biopharmaceutical Companies
Academic and Research Institutes
Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
Latin America
- Brazil
- Argentina
Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Value chain based analysis (Model 2)
- 1.7.3. Multivariate Analysis (Model 3)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
3.3. Technology Landscape
3.4. Pricing Model Analysis
3.5. Industry Analysis Tools
- 3.5.1. Porter's Five Forces Analysis
- 3.5.2. PESTEL Analysis
- 3.5.3. COVID-19 Impact Analysis

Chapter 4. Viral Vaccines CDMO Market: Type Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Viral Vaccines CDMO Market; Type Movement Analysis
4.3. Viral Vaccines CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
4.4. Attenuated Vaccine
- 4.4.1. Attenuated Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Inactivated Vaccine
- 4.5.1. Inactivated Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. DNA Vaccines
- 4.6.1. DNA Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.7. Subunit Vaccines
- 4.7.1. Subunit Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Viral Vaccines CDMO Market: Service Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Viral Vaccines CDMO Market; Service Movement Analysis
5.3. Viral Vaccines CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
5.4. Formulation & Process Development
- 5.4.1. Formulation & Process Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.4.2. Upstream Development
  - 5.4.2.1. Upstream Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.4.3. Downstream Development
  - 5.4.3.1. Downstream development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Analytical Testing
- 5.5.1. Analytical Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Fill-Finish Services
- 5.6.1. Fill-Finish Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7. Packaging & Labeling
- 5.7.1. Packaging & Labeling Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.8. Others
- 5.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Viral Vaccines CDMO Market: Workflow Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Viral Vaccines CDMO Market; Workflow Movement Analysis
6.3. Viral Vaccines CDMO Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
6.4. Clinical
- 6.4.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Commercial
- 6.5.1. Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Viral Vaccines CDMO Market: End Use Estimates & Trend Analysis

7.1. Segment Dashboard
7.2. Viral Vaccines CDMO Market; End Use Movement Analysis
7.3. Viral Vaccines CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
7.4. Biopharmaceutical Companies
- 7.4.1. Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Academic and Research Institutes
- 7.5.1. Academic and Research Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Others
- 7.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Regional Business Analysis

8.1. Regional Dashboard
8.2. Global Viral Vaccines CDMO Market Estimates and Forecasts, by Region, 2021 - 2033 (USD Million)
8.3. North America
- 8.3.1. North America Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.2. U.S.
  - 8.3.2.1. Key Country Dynamics
  - 8.3.2.2. Competitive Scenario
  - 8.3.2.3. Regulatory Framework
  - 8.3.2.4. U.S. Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.3. Canada
  - 8.3.3.1. Key Country Dynamics
  - 8.3.3.2. Competitive Scenario
  - 8.3.3.3. Regulatory Framework
  - 8.3.3.4. Canada Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.4. Mexico
  - 8.3.4.1. Key Country Dynamics
  - 8.3.4.2. Competitive Scenario
  - 8.3.4.3. Regulatory Framework
  - 8.3.4.4. Mexico Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4. Europe
- 8.4.1. Europe Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.2. Germany
  - 8.4.2.1. Key Country Dynamics
  - 8.4.2.2. Competitive Scenario
  - 8.4.2.3. Regulatory Framework
  - 8.4.2.4. Germany Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.3. UK
  - 8.4.3.1. Key Country Dynamics
  - 8.4.3.2. Competitive Scenario
  - 8.4.3.3. Regulatory Framework
  - 8.4.3.4. UK Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.4. France
  - 8.4.4.1. Key Country Dynamics
  - 8.4.4.2. Competitive Scenario
  - 8.4.4.3. Regulatory Framework
  - 8.4.4.4. France Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.5. Italy
  - 8.4.5.1. Key Country Dynamics
  - 8.4.5.2. Competitive Scenario
  - 8.4.5.3. Regulatory Framework
  - 8.4.5.4. Italy Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.6. Spain
  - 8.4.6.1. Key Country Dynamics
  - 8.4.6.2. Competitive Scenario
  - 8.4.6.3. Regulatory Framework
  - 8.4.6.4. Spain Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.7. Denmark
  - 8.4.7.1. Key Country Dynamics
  - 8.4.7.2. Competitive Scenario
  - 8.4.7.3. Regulatory Framework
  - 8.4.7.4. Denmark Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.8. Sweden
  - 8.4.8.1. Key Country Dynamics
  - 8.4.8.2. Competitive Scenario
  - 8.4.8.3. Regulatory Framework
  - 8.4.8.4. Sweden Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.9. Norway
  - 8.4.9.1. Key Country Dynamics
  - 8.4.9.2. Competitive Scenario
  - 8.4.9.3. Regulatory Framework
  - 8.4.9.4. Norway Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5. Asia Pacific
- 8.5.1. Asia Pacific Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.2. Japan
  - 8.5.2.1. Key Country Dynamics
  - 8.5.2.2. Competitive Scenario
  - 8.5.2.3. Regulatory Framework
  - 8.5.2.4. Japan Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.3. China
  - 8.5.3.1. Key Country Dynamics
  - 8.5.3.2. Competitive Scenario
  - 8.5.3.3. Regulatory Framework
  - 8.5.3.4. China Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.4. India
  - 8.5.4.1. Key Country Dynamics
  - 8.5.4.2. Competitive Scenario
  - 8.5.4.3. Regulatory Framework
  - 8.5.4.4. India Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.5. South Korea
  - 8.5.5.1. Key Country Dynamics
  - 8.5.5.2. Competitive Scenario
  - 8.5.5.3. Regulatory Framework
  - 8.5.5.4. South Korea Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.6. Australia
  - 8.5.6.1. Key Country Dynamics
  - 8.5.6.2. Competitive Scenario
  - 8.5.6.3. Regulatory Framework
  - 8.5.6.4. Australia Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.7. Thailand
  - 8.5.7.1. Key Country Dynamics
  - 8.5.7.2. Competitive Scenario
  - 8.5.7.3. Regulatory Framework
  - 8.5.7.4. Thailand Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6. Latin America
- 8.6.1. Latin America Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.2. Brazil
  - 8.6.2.1. Key Country Dynamics
  - 8.6.2.2. Competitive Scenario
  - 8.6.2.3. Regulatory Framework
  - 8.6.2.4. Brazil Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.3. Argentina
  - 8.6.3.1. Key Country Dynamics
  - 8.6.3.2. Competitive Scenario
  - 8.6.3.3. Regulatory Framework
  - 8.6.3.4. Argentina Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7. MEA
- 8.7.1. MEA Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.2. South Africa
  - 8.7.2.1. Key Country Dynamics
  - 8.7.2.2. Competitive Scenario
  - 8.7.2.3. Regulatory Framework
  - 8.7.2.4. South Africa Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.3. Saudi Arabia
  - 8.7.3.1. Key Country Dynamics
  - 8.7.3.2. Competitive Scenario
  - 8.7.3.3. Regulatory Framework
  - 8.7.3.4. Saudi Arabia Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.4. UAE
  - 8.7.4.1. Key Country Dynamics
  - 8.7.4.2. Competitive Scenario
  - 8.7.4.3. Regulatory Framework
  - 8.7.4.4. UAE Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.5. Kuwait
  - 8.7.5.1. Key Country Dynamics
  - 8.7.5.2. Competitive Scenario
  - 8.7.5.3. Regulatory Framework
  - 8.7.5.4. Kuwait Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

9.1. Company Categorization
- 9.1.1. Market Leaders
- 9.1.2. Emerging Players
9.2. Company Market Assessment Analysis, 2024
9.3. Company Profiles
- 9.3.1. Lonza
  - 9.3.1.1. Company overview
  - 9.3.1.2. Financial performance
  - 9.3.1.3. Service benchmarking
  - 9.3.1.4. Strategic initiatives
- 9.3.2. Catalent Pharma
  - 9.3.2.1. Company overview
  - 9.3.2.2. Financial performance
  - 9.3.2.3. Service benchmarking
  - 9.3.2.4. Strategic initiatives
- 9.3.3. Thermo Fisher Scientific
  - 9.3.3.1. Company overview
  - 9.3.3.2. Financial performance
  - 9.3.3.3. Service benchmarking
  - 9.3.3.4. Strategic initiatives
- 9.3.4. Samsung Biologics
  - 9.3.4.1. Company overview
  - 9.3.4.2. Financial performance
  - 9.3.4.3. Service benchmarking
  - 9.3.4.4. Strategic initiatives
- 9.3.5. Fujifilm Diosynth Biotechnologies
  - 9.3.5.1. Company overview
  - 9.3.5.2. Financial performance
  - 9.3.5.3. Service benchmarking
  - 9.3.5.4. Strategic initiatives
- 9.3.6. WuXi Biologics
  - 9.3.6.1. Company overview
  - 9.3.6.2. Financial performance
  - 9.3.6.3. Service benchmarking
  - 9.3.6.4. Strategic initiatives
- 9.3.7. Recipharm AB.
  - 9.3.7.1. Company overview
  - 9.3.7.2. Financial performance
  - 9.3.7.3. Service benchmarking
  - 9.3.7.4. Strategic initiatives
- 9.3.8. HALIX B.V
  - 9.3.8.1. Company overview
  - 9.3.8.2. Financial performance
  - 9.3.8.3. Service benchmarking
  - 9.3.8.4. Strategic initiatives
- 9.3.9. Batavia Biosciences B.V
  - 9.3.9.1. Company overview
  - 9.3.9.2. Financial performance
  - 9.3.9.3. Service benchmarking
  - 9.3.9.4. Strategic initiatives
- 9.3.10. Alcami Corporation
  - 9.3.10.1. Company overview
  - 9.3.10.2. Financial performance
  - 9.3.10.3. Service benchmarking
  - 9.3.10.4. Strategic initiatives

ウイルスワクチンCDMO市場規模、シェア、動向分析レポート：タイプ別、サービス別、ワークフロー別、最終用途別、地域別、セグメント予測、2025年～2033年

Viral Vaccines CDMO Market Size, Share & Trends Analysis Report By Type (Attenuated Vaccine, Inactivated Vaccine, DNA Vaccines, Subunit Vaccines), By Service, By Workflow, By End Use, By Region, And Segment Forecasts, 2025 - 2033

目次

第1章調査手法と範囲

第2章エグゼクティブサマリー

第3章市場の変数、動向、範囲

第4章ウイルスワクチンCDMO市場：タイプの推定・動向分析

第5章ウイルスワクチンCDMO市場：サービスの推定・動向分析

第6章ウイルスワクチンCDMO市場：ワークフローの推定・動向分析

第7章ウイルスワクチンCDMO市場：最終用途の推定・動向分析

第8章地域のビジネス分析

第9章競合情勢

List of Tables

List of Figures

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Market Variables, Trends, & Scope

Chapter 4. Viral Vaccines CDMO Market: Type Estimates & Trend Analysis

Chapter 5. Viral Vaccines CDMO Market: Service Estimates & Trend Analysis

Chapter 6. Viral Vaccines CDMO Market: Workflow Estimates & Trend Analysis

Chapter 7. Viral Vaccines CDMO Market: End Use Estimates & Trend Analysis

Chapter 8. Regional Business Analysis

Chapter 9. Competitive Landscape

ウイルスワクチンCDMO市場規模、シェア、動向分析レポート：タイプ別、サービス別、ワークフロー別、最終用途別、地域別、セグメント予測、2025年～2033年

Viral Vaccines CDMO Market Size, Share & Trends Analysis Report By Type (Attenuated Vaccine, Inactivated Vaccine, DNA Vaccines, Subunit Vaccines), By Service, By Workflow, By End Use, By Region, And Segment Forecasts, 2025 - 2033

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場の変数、動向、範囲

第4章 ウイルスワクチンCDMO市場：タイプの推定・動向分析

第5章 ウイルスワクチンCDMO市場：サービスの推定・動向分析

第6章 ウイルスワクチンCDMO市場：ワークフローの推定・動向分析

第7章 ウイルスワクチンCDMO市場：最終用途の推定・動向分析

第8章 地域のビジネス分析

第9章 競合情勢

List of Tables

List of Figures

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Market Variables, Trends, & Scope

Chapter 4. Viral Vaccines CDMO Market: Type Estimates & Trend Analysis

Chapter 5. Viral Vaccines CDMO Market: Service Estimates & Trend Analysis

Chapter 6. Viral Vaccines CDMO Market: Workflow Estimates & Trend Analysis

Chapter 7. Viral Vaccines CDMO Market: End Use Estimates & Trend Analysis

Chapter 8. Regional Business Analysis

Chapter 9. Competitive Landscape

第1章調査手法と範囲

第2章エグゼクティブサマリー

第3章市場の変数、動向、範囲

第4章ウイルスワクチンCDMO市場：タイプの推定・動向分析

第5章ウイルスワクチンCDMO市場：サービスの推定・動向分析

第6章ウイルスワクチンCDMO市場：ワークフローの推定・動向分析

第7章ウイルスワクチンCDMO市場：最終用途の推定・動向分析

第8章地域のビジネス分析

第9章競合情勢